BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8536236)

  • 1. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
    Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
    Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.
    Sakamoto T; Nomura N; Mori H; Wake N
    Gynecol Oncol; 1996 Nov; 63(2):173-9. PubMed ID: 8910623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer.
    Okamoto A; Sameshima Y; Yokoyama S; Terashima Y; Sugimura T; Terada M; Yokota J
    Cancer Res; 1991 Oct; 51(19):5171-6. PubMed ID: 1680546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 gene analysis of ovarian borderline tumors and stage I carcinomas.
    Kupryjanczyk J; Bell DA; Dimeo D; Beauchamp R; Thor AD; Yandell DW
    Hum Pathol; 1995 Apr; 26(4):387-92. PubMed ID: 7705816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 expression, mutation, and allelic deletion in ovarian cancer.
    McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
    J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
    Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
    Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma.
    Frank TS; Bartos RE; Haefner HK; Roberts JA; Wilson MD; Hubbell GP
    Mod Pathol; 1994 Jan; 7(1):3-8. PubMed ID: 7909153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas.
    Lee SH; Kim JH; Rhee CH; Kang YS; Lee JH; Hong SI; Choi KS
    J Korean Med Sci; 1995 Dec; 10(6):442-8. PubMed ID: 8924230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.
    Gras E; Cortes J; Diez O; Alonso C; Matias-Guiu X; Baiget M; Prat J
    Cancer; 2001 Aug; 92(4):787-95. PubMed ID: 11550149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
    Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
    J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
    Kamiński K; Putowski L; Oleszczuk J
    Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
    Quezado MM; Moskaluk CA; Bryant B; Mills SE; Merino MJ
    Hum Pathol; 1999 Feb; 30(2):203-7. PubMed ID: 10029450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p53 and 17p allelic loss in colorectal carcinoma.
    Cunningham J; Lust JA; Schaid DJ; Bren GD; Carpenter HA; Rizza E; Kovach JS; Thibodeau SN
    Cancer Res; 1992 Apr; 52(7):1974-80. PubMed ID: 1551126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
    Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
    Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 gene mutations and protein accumulation in human ovarian cancer.
    Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.
    von Deimling A; Eibl RH; Ohgaki H; Louis DN; von Ammon K; Petersen I; Kleihues P; Chung RY; Wiestler OD; Seizinger BR
    Cancer Res; 1992 May; 52(10):2987-90. PubMed ID: 1349850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
    McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
    J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
    Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
    Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.
    Frankel RH; Bayona W; Koslow M; Newcomb EW
    Cancer Res; 1992 Mar; 52(6):1427-33. PubMed ID: 1347252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.